First Covid vaccines’ triumph raises hope for cancer fight | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
May 30, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, MAY 30, 2025
First Covid vaccines’ triumph raises hope for cancer fight

Analysis

Naomi Kresge & Robert Langreth, Bloomberg
13 December, 2020, 05:10 pm
Last modified: 14 December, 2020, 11:57 am

Related News

  • Walking 7,000 steps daily or doing simple household chores can cut cancer risk: Study
  • icddr,b launches advanced genome sequencing-based cancer diagnostic services in Bangladesh
  • Cancer prevalence high among children, teenagers in Bangladesh
  • Cancer medicines: Govt slashes source tax to 2%, withdraws VAT for raw materials
  • Cancer accounts for 12% of annual deaths in Bangladesh: BSMMU study 

First Covid vaccines’ triumph raises hope for cancer fight

Naomi Kresge & Robert Langreth, Bloomberg
13 December, 2020, 05:10 pm
Last modified: 14 December, 2020, 11:57 am
Logistics of Vaccine Distribution Are Formidable, Says DeWitt. Photo: Bloomberg
Logistics of Vaccine Distribution Are Formidable, Says DeWitt. Photo: Bloomberg

The first vaccines against Covid-19 aren't just a landmark in the fight against the pandemic. They're also the stepping stone for an unconventional technology that could one day defeat other ailments that have eluded doctors, from cancer to heart disease.

The shots from Moderna Inc. and a partnership of Pfizer Inc. and BioNTech SE use genetic material called messenger RNA to effectively transform the body's own cells into vaccine factories. The approach had never been used outside of clinical experiments, and just how well it worked against the coronavirus stunned even some of its most enthusiastic backers.

Now, with one vaccine vaccine having gained US clearance and the other close behind, the pandemic validation could wrench open a whole new field of medicine.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"We are now entering the age of mRNA therapeutics," said Derrick Rossi, a former Harvard University stem-cell biologist who helped found Moderna in 2010. "The whole world has seen this. There is going to be increased investment and increased resources."

In some ways, the global pandemic was the perfect proving ground for the new technology as deep-pocketed backers -- including Pfizer -- became more willing to take a risk. But the effort was only possible because BioNTech and Moderna Inc. had worked on messenger RNA for years.

The technology instructs cells to make any type of protein, transforming them into tiny production lines for drugs or vaccines. One major drawback is that messenger RNA is fragile, and must reach cells before the body breaks it down. In the coronavirus vaccine, that's done by using a modified form of mRNA and coating it with fatty nanoparticles.

BioNTech's chief executive officer, Ugur Sahin, began studying the technology in cancer some two decades ago with his wife, Ozlem Tureci, an immunologist who co-founded the company. Sahin says what his teams were able to move quickly on the Covid project by harnessing what they had learned from cancer-vaccine development.

The resulting ability to assess multiple candidates in parallel was "really beautiful," Sahin said in an interview.

The cancer field might see its first messenger RNA drug approvals in two or three years, according to Sahin. Rossi meanwhile predicts that virtually all infectious-disease vaccines will use the technology in a decade or two, in part because it's much faster and cheaper. The scientist still owns Moderna shares, but he is no longer affiliated with the company.

There's no guarantee they're right. The risk of failure hangs over every scientific pursuit.

But besides cancer, mRNA companies like Moderna, BioNTech, Translate Bio Inc. and others are working to harness the technology for flu vaccines, a heart failure treatment, cystic fibrosis, a common pathogen called cytomegalovirus, and perhaps the biggest challenge of all: HIV, which has eluded vaccine researchers for four decades.

Stephane Bancel, Moderna's chief executive officer, recalls warning his wife when he left an established diagnostics company almost a decade ago that his new employer had less than a 5% chance of success. But if they did, he told her, the upside would be massive.

"It is not going to be a one-drug company," he recalled saying in a telephone interview. "Either we fail and it is zero, or we succeed and it is an industry."

Stephane BancelPhotographer: Adam Glanzman/Bloomberg
Stephane BancelPhotographer: Adam Glanzman/Bloomberg

One relatively quick win for messenger RNA could be better vaccines for seasonal flu. Influenza kills as many as 650,000 people each year, and existing vaccines are often only partly effective because production needs to start about six months early, based on health officials' educated guesses about which strains are most likely to circulate at that point.

The production could start later and involve less guesswork with mRNA. "If you got close to what the coronavirus vaccine is showing, that would be a major improvement," said Matthias Kromayer, a partner at MIG AG, an early venture capital backer of BioNTech.

And if people need periodic booster shots against Covid, the flu vaccines could be combined with a coronavirus booster to wipe out all winter respiratory viral worries in one shot, according to Moderna's Bancel.

More importantly, messenger RNA may help produce vaccines against viruses that have evaded conventional approaches. After Covid, Moderna's most advanced program is a vaccine against cytomegalovirus, which can cause birth defects when passed from pregnant mother to unborn child. Scientists have been trying to develop a shot against this virus for 50 years, but Moderna believes mRNA technology gives it an edge. Early results from mid-stage trials are promising, and final-stage trials could begin next year.

Big Pharma's Interest

The company is also working on cancer vaccines with drugmaker Merck & Co. In a study with presented in November, a Moderna vaccine combined with Merck's blockbuster immune drug Keytruda helped shrink tumors in 5 of 10 patients with of advanced head and neck cancer.

Besides Merck, other big drugmakers from AstraZeneca Plc to Roche Holding AG are getting involved. There is no doubt that mRNA will be an important method going forward, according to Severin Schwan, Roche's chief executive. Roche, one of the world's biggest maker of oncology drugs, is working with BioNTech on developing personalized cancer vaccines.

"The door is opened up here," Schwan said in an interview. "It's reconfirmed now via Covid-19, because this is real clinical data. That's a good reason to further invest."

Besides Covid-19, though, almost all of the mRNA drugs and vaccines remain at early stages of human testing. And while the recent success may bode well for other infectious-disease vaccines, the implications in oncology are less clear because cancer has developed numerous defenses to evade the immune system.

"We can't just simply say that because we have seen the validation in the mRNA vaccine field, any other mRNA vaccine will also work," says BioNTech's Sahin. "Every approach has to address different biological and medical challenges."

Treating Cancer

Most of BioNTech's research outside of Covid is focused on cancer. There, the idea is not to prevent disease but to treat it. The company is trying several different approaches, with a view to finding telltale sequences on a person's tumor and coding mRNA to tell immune cells how to attack those tumor cells.

The cash flow from the coronavirus vaccine success will enable the German biotech to push forward its patient trials in cancer as well. One of BioNTech's cancer vaccines spurred strong responses and in some cases shrank tumors in patients with advanced melanoma in an 89-person trial published this summer. The first efficacy data from patient studies in cancer could come as soon as the end of next year or early in 2022, according to the CEO.

BioNTech is also working with the Bill and Melinda Gates Foundation on an mRNA approach against HIV, which has eluded vaccine researchers so far because the virus is able to hide within cells. Human tests haven't started yet on the project.

Science Fiction

Some potential future uses sound a little like science fiction for now. BioNTech is doing early research into whether mRNA can be used to reprogram cells for regenerative medicine. In the future, scientists may also be able to designed targeted nanoparticles that accumulate in particular types of tissue such as bone marrow, said Drew Weissman, an immunologist at the University of Pennsylvania who helped develop mRNA technology used in both the Pfizer-BioNTech and Moderna vaccines. That could allow doctors to treat genetic diseases such as sickle cell anemia with a simple intravenous injection of targeted mRNA therapy.

Disclaimer: This article first appeared on bloomberg.com, and is published by special syndication arrangement.

Top News

Covid / vaccines / cancer

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Deep depression over Bay of Bengal on 29 May. Photo: ANI
    Heavy rain, tidal surges trigger flood warnings as deep depression crosses coast
  • Powerful tidal surges from the Meghna River flooded more than 100 villages in four coastal upazilas of Lakshmipur on 29 May 2025. Photo: TBS
    Meghna tidal surge floods over 100 villages as incessant daylong rain batters Lakshmipur
  • Attackers vandalise the windows of the residence of Jatiyo Party (JaPa) Chairman GM Quader and set fire to a motorcycle in Rangpur on 29 May 2025. Photo: TBS
    Jatiyo Party chief GM Quader's Rangpur house attacked; NCP, SAD activists blamed

MOST VIEWED

  • Dhaka areas at a gridlock on Wednesday, 28 May 2025. Photo: Syed Zakir Hossain/TBS
    BNP, Jamaat rallies: Traffic clogs Dhaka roads, including Motijheel, Paltan, Dainik Bangla intersection
  • IFIC Bank receives Tk6,000 cr in new deposits in six months
    IFIC Bank receives Tk6,000 cr in new deposits in six months
  • Mohammad Abdul Mannan, chairman FSIB Ltd. Sketch: TBS
    FSIB to bounce back soon
  • Abdul Awal Mintoo, chairman of National Bank Limited. Sketch: TBS
    'Regulatory support must for National Bank to restore depositors' confidence'
  • Md Nazrul Islam Swapan, chairman of EXIM Bank. Sketch: TBS
    Exim Bank restored depositors’ confidence, overcoming challenges
  • Mohammad Mamdudur Rashid, managing director and CEO, UCB. Sketch: TBS
    Customers’ trust and confidence fueling deposit growth at UCB

Related News

  • Walking 7,000 steps daily or doing simple household chores can cut cancer risk: Study
  • icddr,b launches advanced genome sequencing-based cancer diagnostic services in Bangladesh
  • Cancer prevalence high among children, teenagers in Bangladesh
  • Cancer medicines: Govt slashes source tax to 2%, withdraws VAT for raw materials
  • Cancer accounts for 12% of annual deaths in Bangladesh: BSMMU study 

Features

For hundreds of small fishermen living near this delicate area, sustainable fishing is a necessity for their survival. Photo: Syed Zakir Hossain

World Ocean Day: Bangladesh’s ‘Silent Island’ provides a fisheries model for the future

8h | The Big Picture
The university will be OK. But will the US? Photo: Bloomberg

A weaker Harvard is a weaker America

8h | Panorama
The Botanical Garden is a refuge for plant species, both native and exotic. Photo: Mehedi Hasan/TBS

The hidden cost of 'development' in the Botanical Garden

8h | Panorama
Stillbirths in Bangladesh: A preventable public health emergency

Stillbirths in Bangladesh: A preventable public health emergency

9h | Panorama

More Videos from TBS

Record migrant deaths in 2024

Record migrant deaths in 2024

5h | Podcast
News of The Day, 29 MAY 2025

News of The Day, 29 MAY 2025

7h | TBS News of the day
Businesses set for relief as interim govt eyes major tax & fine cuts

Businesses set for relief as interim govt eyes major tax & fine cuts

10h | TBS Insight
Love is essential for human life

Love is essential for human life

10h | TBS Programs
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net